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Abstract
Background: Despite intense effort the treatment options for the invasive astrocytic tumors are
still limited to surgery and radiation therapy, with chemotherapy showing little or no increase in
survival. The generation of Serial Analysis of Gene Expression (SAGE) profiles is expected to aid in
the identification of astrocytoma-associated genes and highly expressed cell surface genes as
molecular therapeutic targets. SAGE tag counts can be easily added to public expression databases
and quickly disseminated to research efforts worldwide.
Methods: We generated and analyzed the SAGE transcription profiles of 25 primary grade II, III
and IV astrocytomas [1]. These profiles were produced as part of the Cancer Genome Anatomy
Project's SAGE Genie [2], and were used in an in silico search for candidate therapeutic targets by
comparing astrocytoma to normal brain transcription. Real-time PCR and immunohistochemistry
were used for the validation of selected candidate target genes in 2 independent sets of primary
tumors.
Results: A restricted set of tumor-associated genes was identified for each grade that included
genes not previously associated with astrocytomas (e.g. VCAM1, SMOC1, and thymidylate
synthetase), with a high percentage of cell surface genes. Two genes with available antibodies,
Aquaporin 1 and Topoisomerase 2A, showed protein expression consistent with transcript level
predictions.
Conclusions: This survey of transcription in malignant and normal brain tissues reveals a small
subset of human genes that are activated in malignant astrocytomas. In addition to providing
insights into pathway biology, we have revealed and quantified expression for a significant portion
of cell surface and extra-cellular astrocytoma genes.
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Background
Astrocytomas are the most frequent malignant primary
brain tumors in adults. Clinically, this group of tumors
can be divided into four World Health Organization
(WHO) grades. Pilocytic astrocytomas (WHO grade I) are
generally slow growing and non-infiltrative pediatric
tumors, which are rarely fatal. For the infiltrating astrocy-
tomas, survival decreases with increasing grade. Grade II
astrocytomas patients survive an average of over 5 years,
but survival drops to 3 years for anaplastic astrocytomas
(grade III). Grade IV astrocytomas (glioblastoma multi-
forme or GBM) account for about half of all astrocytic
tumors, with a median survival of less than a year. Effec-
tive treatment options for the invasive grade II to IV
tumors are still limited to surgery and radiation therapy,
with most chemotherapy regimens showing little or no
increase in survival.
Several recent gene expression profiling studies of human
astrocytomas have been able to distinguish between vari-
ous grades of astrocytomas and between astrocytomas
and other human glial tumors, and to identify new molec-
ular classes within histological grade [3-7]. This enhanced
molecular classification based on expression patterns of
genes and pathways holds promise for better diagnostic
and prognostic tools. Candidate glioblastoma associated
genes have also been identified using expression profiling
[8-11]. While these studies in brain cancers have produced
leads for potential therapeutic targets, a systematic and
comprehensive evaluation of gene expression in malig-
nant astrocytomas is not readily and freely available for
the scientific community.
In this study, we sought to create a public and comprehen-
sive gene expression resource for astrocytomas, with the
primary intention of aiding searches for new therapeutic
targets in malignant astrocytomas. For this purpose we
produced and analyzed in detail 25 gene expression pro-
files of primary astrocytic tumors (grade II, III and IV)
using Serial Analysis of Gene Expression (SAGE) [12].
Complete expression profiles are posted for the scientific
community at the CGAP SAGE Genie website http://
cgap.nci.nih.gov/SAGE[2]. The utility of the resource was
validated by extensive comparisons of tumor with normal
tissue. SAGE profiles on normal brain and other tissues
created by the Cancer Genome Anatomy Project [8] were
used to subtract out the genes normally expressed in adult
brain, leaving a small and specific set of astrocytoma asso-
ciated genes for each class, and revealing cell surface or
extra-cellular matrix related genes highly expressed in the
tumors when compared to their expression in normal tis-
sue. A subset of the tumor-associated genes was validated
in an independent set of tumors at both the transcript and
protein level. In summary we have identified several novel
tumor-associated markers in astrocytic tumors as well as
various cell surface markers highly expressed in the most
aggressive tumor types.
Methods
Tissue and RNA
Astrocytic tumor samples from 21 adults and 4 children
were obtained from the Duke Brain Tumor Bank. All sam-
ples were classified based on histology according to the
World Heath Organization grading criteria. Pediatric nor-
mal cortex (15 months) was a gift of Dr. Rachel Myerowitz
and normal pediatric cerebellum was from the Maryland
Brain Bank. Normal adult cortex and cerebellum were
rapid autopsy samples obtained from the Duke Alzhe-
imer's Brain Bank. Total RNA from normal substantia
nigra was obtained from Clontech (Palo Alto, CA).
PolyA+ RNA from normal adult leukocytes was obtained
from Stratagene (La Jolla, CA), as noted for each library's
information at the SAGE Genie Website [2]. RNA integrity
was confirmed by gel electrophoresis prior to SAGE
library construction.
SAGE libraries and informatics
SAGE libraries from 25 selected astrocytomas: 8 grade II
astrocytomas, 10 grade III anaplastic astrocytomas and 7
grade IV glioblastomas (primary GBM) were constructed
using Nla III as the anchoring enzyme and BsmF I as the
tagging enzyme using a micro-SAGE protocol. The SAGE
library clones were partially arrayed at Lawrence Liver-
more National Laboratories and inserts were purified and
sequenced at the BC Cancer Agency Genome Sciences
Centre or arrayed and sequenced at Agencourt Bioscience
Corporation.
The SAGE 2000 software version 4.12 (available at http://
www.sagenet.org) was used to extract SAGE tags from the
original sequence files, remove duplicate ditags, remove
linker sequences, remove one base pair variations of
linker sequences and tabulate the occurrence of each tag.
Tag sequences, tag counts and gene associations were
stored in a Microsoft Access relational database for subse-
quent selection of tags with a particular profile. A total of
2,605,122 tags were obtained with an average of 102,988
tags per library. Normal neural tissue tags included a total
of 443,560 tags from normal brain [8,13]. These SAGE
normal brain libraries have the following unique identifi-
ers: cortex_B_BB542; cortex_B_pool6; thalamus_B_1;
cerebellum_B_1; cerebellum_B_BB542;
peds_cortex_B_H1571 and substantia_nigra_B_1. Tags
totaling 48,039 were also included from normal leuko-
cytes (SAGE_Leukocytes_normal_B_1). Detailed library
information and tag counts for each tissue are located at
CGAP's SAGE Genie http://cgap.nci.nih.gov/SAGE[2]. Tag
counts were normalized to 100,000 tags per library.BMC Cancer 2004, 4:39 http://www.biomedcentral.com/1471-2407/4/39
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Real-time PCR
Total RNA extraction, cDNA synthesis and quantitative
PCR were performed as previously described [1]. Gene
expression levels were normalized to 3 genes; GAPDH,
ribosomal protein RPS27 and low molecular mass ubiqui-
none-binding protein (QP_C). Both RPS27 and QP-C
showed a relatively even expression level across the librar-
ies as assed by SAGE analysis. Relative expression levels
were calculated in comparison to the levels in nine nor-
mal neural tissues, including normal brain (3x), cerebel-
lum (2x), thalamus, gray matter, caudate nucleus and
pediatric cortex according to Saha et al., 2001 [14]. A list
of the PCR primers used for each gene is available upon
request.
Immunohistochemistry
Formalin-fixed 5-µm paraffin-embedded sections were
stained with various antibodies using the biotin/streptavi-
din RTU Vectastain Universal Quick kit (Vector laborato-
ries, Burlingame, CA) as previously described [1]. Shortly,
sections were deparaffinized in HemoD and re-hydrated
through descending alcohols. Endogenous peroxidase
was quenched by incubating the slides in methanol/5%
H2O2 at room temperature for 10 min. Non-enzymatic
antigen retrieval was performed using the Antigen
retrieval solution AR or Citra (Biogenex, San Ramon, CA)
in combination with microwave treatment. Sections were
then blocked in PBS/0.5% Triton X-100 containing 2.5%
normal horse serum for at least 30 min at room tempera-
ture and incubated with primary antibody overnight at
4°C. The primary antibodies used were mouse mono-
clonal anti-aquaporin1, at a 1:60 dilution (Abcam Lim-
ited, Cambridgeshire, United Kingdom) and mouse
monoclonal anti-Topoisomerase II Alpha used at a 1:30
dilution (Novocatra Laboratories, New Castle, United
Kingdom). Sections were developed with a DAB (Sigma,
St. Louis, MO) substrate, counterstained with hematoxy-
lin and mounted with Cytoseal-60.
Tissue micro arrays
The tissue micro array used in these studies contained
cores from 20 glioblastomas, 20 anaplastic astrocytomas,
20 infiltrating astrocytomas and 20 oligodendroglial
lesions and was prepared according to methods described
by Kononen and Kallioniemi [15]. Microscopic examina-
tion of the array confirmed that the appearance of the
tumor tissue cores corresponded to that in the donor
blocks. A neuropathologist (CGE) selected the tumor
areas sampled in each case and examined the resulting
arrays to ensure they accurately represented the donor
cases.
Results and Discussion
SAGE gene expression profiles, selection and confirmation 
of tumor-associated genes
This report describes the comprehensive generation of
expression profiles of three astrocytic tumor grades based
on Serial Analysis of Gene Expression (SAGE). The main
goals were to identify genes not expressed in normal brain
tissue and genes highly expressed in the more aggressive
astrocytomas encoding cell surface or extra-cellular matrix
related proteins that could be of potential therapeutic
interest. We generated SAGE profiles on 8 infiltrating
astrocytomas, 10 anaplastic astrocytomas and 7 glioblast-
oma samples. Combined with two glioblastoma profiles
[8], previously deposited on SAGE Genie, this study ana-
lyzed 2,734,106 astrocytoma SAGE tags. On average we
could distinguish over 27,000 unique tags in each tumor
grade after excluding those with single counts (Table 1).
Complete expression profiles and library information are
posted for the scientific community at the Cancer
Genome Anatomy Project (CGAP) SAGE Genie website
http://cgap.nci.nih.gov/SAGE, where the libraries can be
downloaded or viewed online using SAGE Genie tools [2].
In order to identify tumor-associated genes, we sought
highly expressed transcripts in each grade of astrocytoma
that were not expressed in 7 normal brain tissues. This
also helped control for contaminating normal cells within
the tumor sample. Tags expressed in a normal leukocyte
SAGE library were also included in the analysis so they
could be subtracted to reduce the chances of identifying
transcripts from white blood cells that frequently infiltrate
these tumors. Initially we selected for tags with an average
expression of at least 3 per 100,000 tags. Subsequently, we
selected for tags expressed at less than 2 counts per
Table 1: Summary of number of tag sequences.
Group Total tags Unique tagsa Expressed tags per 
libraryb
Expressed in tumors and not in 
neural normalsc
Grade II 869,992 22,574 3,999 41
Grade III 1,026,620 26,445 3,866 55
Grade IV 798,451 33,541 3,518 76
aUnique tags with a tag count of 2 and higher. bAmount of tags with an expression level of 3 or more per 100,000 tags. cAmount of tags expressed 
in at least 20% of the tumors and with an expression level of 2 or less in the normal neural tissues and leukocytes.BMC Cancer 2004, 4:39 http://www.biomedcentral.com/1471-2407/4/39
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100,000 in each of the 8 normal libraries (7 normal neu-
ral tissues & one leukocyte), reducing the number of tags
to less than 100 per tumor type (Table 1). We further nar-
rowed down the list of candidates by including only those
tag sequences that could be matched with a full-length
cDNA sequence. From these lists of genes we selected
respectively 8, 16 and 10 genes for real-time PCR analysis
in an independent set of 14 to 17 grade II, grade III and
grade IV primary tumors. Only 6 genes could not be con-
firmed by real-time PCR analysis, 3 of 8 (grade II selec-
tion) and 3 of 16 (grade III selection). Another 8 genes
were confirmed in only 20 to 25 % of the tumors. Table 2
lists those genes with a 5-fold or more over-expression by
real time PCR in at least 30% of the tumor samples from
the corresponding grade, when compared to an average of
the normal neural tissue expression. The results show that
the in silico selection using SAGE profiles revealed tumor-
associated genes that can be found in a different set of pri-
mary tumors implying a possible role for these genes in
tumor development and increasing their value as putative
therapeutic targets.
The limited availability of high quality antibodies for the
identified tumor-associated genes (Table 2) narrowed our
study at the protein level to those genes that had previ-
ously been implicated in astrocytic tumors. Monoclonal
antibodies for TOP2A and AQ1 were used to analyze the
expression at the protein level in individual glioblastoma
sections and in a tissue micro-array. Strong nuclear stain-
ing in 5 of 8 individual glioblastomas tested was found for
TOP2A (Figure 1A,1C and 1D). The GBMs showed
intensely staining cells with the percentage of positive
Table 2: Astrocytoma associated genes validated by real-time PCR.
Tag sequence Symbol Gene/Ontology Mean tumora Mean normalb % SAGEc % RT-PCRd
Low grade astrocytomas (grade II)
TGGGATTCCC CHI3L2 Chitinase 3-like 2 / cartilage biogenesis, extra-
cellular
10.8 0 25 57
ATCTGCTCGG NMB Neuromedin B / signal transduction, neuropeptide 9.1 0.1 38 57
GTCAGAACTT cDNA FLJ22528 / unknown 5.8 0.3 38 43
GTACGGAGAT VCAM1 Vascular cell adhesion molecule 1/ cell adhesion 4.4 0.2 50 29
Anaplastic astrocytomas (grade III)
TGGGATTCCC CHI3L2 Chitinase 3-like 2 / cartilage biogenesis, extra-
cellular
12.3 0 30 63
GTGCGGAGGA SAA1 Serum amyloid A1/ inflammatory response, lipid 
metabolism, extra-cellular
11.4 0 20 50
TTTGCACTTT SMOC1 Secreted modular calcium-binding 1/ calcium ion 
binding
6.0 0 50 50
CCATTGTGGA ADORA3 Adenosine A3 receptor / signal transduction, G-
protein coupled receptor
4.1 0.1 60 50
ATCTGCTCGG NMB Neuromedin B/ signal transduction, neuropeptide 9.1 0.1 40 81
CGCGGCGGCG CRF C1q-related factor / function unknown 7.8 0.1 70 56
CCCAGTAAGA CSRP2 Cysteine and glycine-rich protein 2 / cell 
differentiation/growth, LIM domain protein
9.4 0.2 80 44
GTACGGAGAT VCAM1 Vascular cell adhesion molecule 1/ cell adhesion 3.0 0.2 20 69
Glioblastomas (grade IV)
ACTGTCGCCA AQP1 aquaporin 1 / water transport, ion channel 5.8 0 22 53
ATGTAGAGTG TYMS thymidylate synthetase / pyrimidine metabolism 7.1 0 67 71
CTCAGCAATG TOP2A topoisomerase (DNA) II alpha (170 kD) / DNA 
metabolism, isomerase
4.2 0 44 88
GTCAACAGTA ABCC3 ATP-binding cassette, subfamily C, member 3/ 
multidrug resistance, transport protein
12.3 0 89 94
GTGCGGAGGA SAA1 serum amyloid A1/ inflammatory response, lipid 
metabolism, extra-cellular
14.3 0 44 53
TGGGATTCCC CHI3L2 chitinase 3-like 2 / cartilage biogenesis, extra-
cellular
31.3 0 67 100
ATCTGCTCGG NMB Neuromedin B / signal transduction, neuropeptide 4.6 1 44 53
GTTTATGGAT MGP Matrix Gla protein /cartilage condensation, 
ossification, extra-cellular
72 5 6 3 5
All counts are normalized per 100,000 tags. aAverage tag count per individual tumor SAGE library. bAverage tag count per individual normal neural 
tissue SAGE library. cPercentage of tumor SAGE libraries with an expression of at least 5 or more counts. dPercentage of tumor samples in an 
independent panel of tumors with at least a 5-fold of more over-expression when compared to neural normal tissue samples in real-time PCR 
analysis.BMC Cancer 2004, 4:39 http://www.biomedcentral.com/1471-2407/4/39
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cells varying between 3 and 10%. Similar results were
obtained when staining a tissue micro-array containing a
different set of 20 GBMs. In six cases we found 5 to 10%
of the cells expressing TOP2A. The percentage of strong
positive cells among the 20 anaplastic astrocytomas
present on the tissue micro array was lower and estimated
to be 2 – 3% in 10 cases. Normal neural brain tissues like
cortex, white matter, spinal cord and hippocampus where
negative for TOP2A (Figure 1B). Cytoplasmatic staining
was observed when anti-aquaporin 1 monoclonal anti-
bodies were used. Three of 5 individual GBM sections
where positive, with examples shown in Figures 1F and
1G. These results emphasize that the high transcript levels
of TOP2A and Aquaporin 1 correlate well with a high
protein level in a third independent set of tumors, imply-
ing that this might also be the case for the other identified
tumor-associated genes as listed in Table 2 and Table 3.
Potential therapeutic targets in astrocytic tumors
Encouraged by the confirmation of our initial in silico
analysis for tumor-associated genes we formulated a
slightly simplified approach to find cell surface, extra-cel-
Representative immunostaining of paraffin sections with antibodies against Topoisomerase 2A and Aquaporin 1 Figure 1
Representative immunostaining of paraffin sections with antibodies against Topoisomerase 2A and Aquaporin 
1. (A) Upper panel shows two TOP2A positive cores from GBMs; lower panel shows two negative cores on the same tissue 
micro-array. (B) Upper panel from left to right: cortex and white matter; lower panel from left to right: spinal cord and hypoc-
ampus. All stained with anti-TOP2A antibodies. (C – D) Paraffin section of GBM showing nuclear staining of TOP2A; D shows 
a higher magnification and E is the corresponding negative control with mouse IgG1 and no primary antibodies. (F – G) Paraf-
fin section of GBM showing cytoplasmatic staining with anti-aquaporin 1 antibodies; G shows a higher magnification and H is 
the negative control.BMC Cancer 2004, 4:39 http://www.biomedcentral.com/1471-2407/4/39
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lular matrix and cell adhesion related genes. We selected
for transcript tags with at least a ten fold over-expression
when compared to the average expression level in normal
neural brain tissues. Next we applied a filter that would
include only those tags with an average expression of at
least 5 or 10 counts per 100,000 tags in 30% or more of
the tumors, respectively for anaplastic astrocytomas and
glioblastomas. The generated lists of transcript tags were
mapped to the corresponding gene using SAGE Genie,
where after the gene ontology information (if available)
was used as a final filter to identify membrane, cell surface
and cell adhesion related genes (Table 3). Interestingly,
almost 50% of the genes identified as highly expressed in
both tumor types have not previously been implicated in
astrocytomas and are potential new therapeutic targets.
Table 3: Selected highly expressed genes in grade III and IV astrocytomas.
Tag Sequence Tumora Inductionb Gene Gene Ontology
Anaplastic astrocytomas (Grade III)
AAGCCGAAGA 10 40 GFAP glial fibrillary acidic protein Major intermediate filament protein of mature astrocytes
CTGGGGAGTG 8.1 22 VAPB VAMP associated protein B and C Type IV membrane protein in plasma and intracellular 
vesicle membranes
GCAACAGCAA 80.9 19 SEC61G Sec61 gamma subunit Endoplasmatic reticulum membrane protein, 
translocation
TTAATCTGAG 6.9 18 ARHGEF6 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6, 
intra-cellular
ATCTTGTTAC 11 15 FN1 fibronectin 1 Extra-cellular matrix, cell adhesion, cell migration
GGAACAAACA 11.9 14 CD24 Plasma membrane, small cell lung carcinoma cluster 4 
antigen
AGGGAGGGGC 32.9 14 GPX3 glutathione peroxidase 3 Extra-cellular, response to oxidative stress, glutathione 
metabolism
GTATGGGCCC 26.8 13 CHI3L1 chitinase 3-like 1 Cartilage glycoprotein
ACGAGGGGTG 71.4 12 BCAN, chondroitin sulfate proteoglycan Cell adhesion
CACTTGAAAA 6.9 11 CALU calumenin Endoplasmatic reticulum, calcium ion binding
GATAACTACA 6.7 11 IGFBP7 Extra-cellular, insulin-like growth factor binding protein 7
TCCTGTAAAG 6.8 11 CAV1 caveolin 1, 22 kDa Plasma membrane, caveolae protein, integrin-mediated 
celladhesion, vesicular trafficking
GTCTTAAAGT 41.8 10 SOD2 Superoxide dismutase, mitochondrial, erythropoietin-
mediated neuro protection through NF-kB
Glioblastomas (grade IV)
GTATGGGCCC 144.2 72 CHI3L1 chitinase 3-like 1 Cartilage glycoprotein
GACCACCTTT 17.3 69 MFAP2 microfibrillar-associated protein 
2
Major antigen of elastin-associated microfibrils
ACCAAAAACC 115.8 49 COL1A1 collagen, type I, alpha 1 Extra-cellular matrix
AGTGGTGGCT 14.8 39 FMOD fibromodulin Extra-cellular matrix, TGF beta receptor complex 
assembly
CTGGGGAGTG 13.2 35 VAPB VAMP associated protein B and C Type IV membrane protein in plasma and intracellular 
vesicle membranes
ACATTCTTTT 38.2 34 GPNMB glycoprotein nmb Transmembrane glycoprotein
ATCTTGTTAC 21.1 28 FN1 fibronectin 1 Extra-cellular matrix, cell adhesion, cell migration
GCAACAGCAA 97.9 23 SEC61G Sec61 gamma subunit Endoplasmatic reticulum membrane protein, 
translocation
TCACCAAAAA 19.3 19 STAB1 stabilin 1 Cell adhesion, calcium ion binding
CACTTGAAAA 11.6 19 CALU calumenin Endoplasmatic reticulum, calcium ion binding
TTTTCAAATA 15.4 15 T1A-2 lung type-I Type I integral membrane glycoprotein
GTCTTTCTTG 24.4 14 RAB13 Cell adhesion, member RAS oncogene family
GGAAATGTCA 12.6 13 MMP2 matrix metalloproteinase Extra-cellular matrix, calcium ion binding
GTACTAGTGT 23.8 12 CCL2 chemokine (C-C motif) ligand 2 Extra-cellular matrix, cell adhesion, signal transduction
AAGCTGTATA 16.7 12 TNC tenascin C (hexabrachion) Extra-cellular matrix, cell adhesion
GTGCTAAGCG 10.8 11 COL6A2 collagen, type VI, alpha 2 Extra-cellular matrix
CATATCATTA 151.6 11 IGFBP7 Extra-cellular, insulin-like growth factor binding protein 7
AACACAGCCT 24.9 11 C4A complement component 4A Extra-cellular matrix, complement pathway
Highly expressed genes were selected with at least a ten fold over-expression when compared to normal neural tissue and a minimal expression 
level of at least 5 or 10 counts per 100,000 tags (in respectively grade III and IV tumors) in 30% of the corresponding tumor type. aAverage tag 
count count per individaul tunor SAGE library. bAverage induction factor.BMC Cancer 2004, 4:39 http://www.biomedcentral.com/1471-2407/4/39
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Intracellular proteins that contribute to the fusion of the
vesicles with the plasma membrane during exocytosis
include synaptosomal protein and vesicle-associated
membrane proteins (VAMP). Both anaplastic astrocyto-
mas and glioblastomas show high expression of VAPB
and anaplastic astrocytomas express caveolin1 (Table 3).
It has been shown that caveolae require intact VAMP for
targeted transport in endothelial cells. Caveolae and asso-
ciated proteins might be targeted in cancer as recently sug-
gested [16].
One of the other genes expressed in common between the
three astrocytomas is chitinase 3-like 2 (CHI3L2) or YKL-
39 (Table 2). CHI3L2 is a chondrocyte growth related gene
and is an antigen found in rheumatoid arthritis [17] and
osteoarthritis and a possible immunotherapy target.
Another commonly over-expressed gene is Neuromedin B.
This neuropeptide has been implicated as an autocrine
growth factor in lung cancer cells [18] that binds to a G
protein-coupled receptor on the cell surface and might
have a similar role in astrocytic tumors. It is tempting to
speculate that a specific neuropeptide antagonist or neu-
tralizing antibodies might reduce astrocytoma growth.
Neuromedin B had previously been described as a GBM
marker [9], and was included along with ABCC3 in the
real-time PCR analysis as a positive control.
Another relatively unknown gene is the recently character-
ized SMOC-1 [19], which was identified as a grade II and
III tumor-associated gene (Table 2). This gene is related to
SPARC/osteonectin, which was reported to participate in
angiogenesis and tumor formation of human melanomas.
Another extra cellular gene, Matrix Gla protein [20] had
increased expression levels in higher-grade astrocytomas.
MGP helps regulate the calcification of the extra cellular
matrix [20].
Aquaporin 1 is an integral membrane protein important
in the regulation of water transport in various epithelial
and endothelial cell types [21]. The over-expression of
AQP1 in human brain tumors was described in a limited
array study of 4 Glioblastomas [11] and it has been sug-
gested that the protein might play a role in brain tumor
edema in a similar way as the closely related aquaporin-4
[22]. Although the specific role of AQP1 in brain tumors
is still unknown, our demonstration that AQP1 is consist-
ently expressed in GBM may prompt other studies.
Thymidilate synthetase and Topoisomarese 2A were over-
expressed in glioblastoma as well as in our previous study
of medulloblastoma [1]. Considering the role of Top2A as
a molecular target of various anticancer drugs, and its
identification as a survival marker in astrocytomas [23],
its over-expression at the protein level in multiple brain
tumors and the development of TOP2A inhibitors [24]
makes the molecular targeting of TOP2A worthy of further
investigation.
In summary we have identified a number of new tumor-
associated genes for three different grades of astrocytic
tumors, and helped re-confirm in a larger set of samples
several previously known astrocytoma genes. Despite the
high heterogeneity among gliomas, a small set of genes is
consistently observed at high levels in more than a third
of each grade of astrocytoma studied. Many other cell sur-
face, extra-cellular matrix or cell adhesion genes have been
identify as potential targets for cancer therapy in astrocytic
tumors. Although the therapeutic value of these markers is
speculative at this point, by integrating this data onto the
commonly used gene expression resource, SAGE Genie,
this data can be used as a standard to determine gene
expression in astrocytomas. Further evaluation by in vitro
and in vivo studies will be necessary to establish the role of
these over-expressed genes in brain tumor development
and progression.
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